231 related articles for article (PubMed ID: 34650924)
1. Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.
Tao Z; Liu J; Li T; Xu H; Chen K; Zhang J; Zhou H; Sun J; Han J; Guo Z; Yang H; Cao WM; Hu X
Front Oncol; 2021; 11():741142. PubMed ID: 34650924
[TBL] [Abstract][Full Text] [Related]
2. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
[TBL] [Abstract][Full Text] [Related]
3. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract][Full Text] [Related]
4. Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling.
Wang T; Wei L; Lu Q; Shao Y; You S; Yin JC; Wang S; Shao Y; Chen Z; Wang Z
NPJ Precis Oncol; 2022 Nov; 6(1):84. PubMed ID: 36369474
[TBL] [Abstract][Full Text] [Related]
5. Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.
Xu H; Shen J; Xiang J; Li H; Li B; Zhang T; Zhang L; Mao X; Jian H; Shu Y
Cancer Manag Res; 2019; 11():6343-6351. PubMed ID: 31372039
[No Abstract] [Full Text] [Related]
6. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
Zhu VW; Klempner SJ; Ou SI
Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
[TBL] [Abstract][Full Text] [Related]
7. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.
Schrock AB; Zhu VW; Hsieh WS; Madison R; Creelan B; Silberberg J; Costin D; Bharne A; Bonta I; Bosemani T; Nikolinakos P; Ross JS; Miller VA; Ali SM; Klempner SJ; Ou SI
J Thorac Oncol; 2018 Sep; 13(9):1312-1323. PubMed ID: 29883838
[TBL] [Abstract][Full Text] [Related]
8. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
Singh H; Li YY; Spurr LF; Shinagare AB; Abhyankar R; Reilly E; Brais LK; Nag A; Ducar MD; Thorner AR; Shapiro GI; Keller RB; Siletti C; Clark JW; Farago AF; Lin JJ; Demetri GD; Gujrathi R; Kulke MH; MacConaill LE; Ligon AH; Sicinska E; Meyerson ML; Meyerhardt JA; Cherniack AD; Wolpin BM; Ng K; Giannakis M; Hornick JL; Cleary JM
Clin Cancer Res; 2021 Mar; 27(6):1695-1705. PubMed ID: 33414136
[TBL] [Abstract][Full Text] [Related]
9. Genomic Features of Solid Tumor Patients Harboring
Dai Y; Liu P; He W; Yang L; Ni Y; Ma X; Du F; Song C; Liu Y; Sun Y
Front Oncol; 2022; 12():813158. PubMed ID: 35785159
[TBL] [Abstract][Full Text] [Related]
10. Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.
Ross DS; Liu B; Schram AM; Razavi P; Lagana SM; Zhang Y; Scaltriti M; Bromberg JF; Ladanyi M; Hyman DM; Drilon A; Zehir A; Benayed R; Chandarlapaty S; Hechtman JF
Ann Oncol; 2020 Aug; 31(8):991-1000. PubMed ID: 32348852
[TBL] [Abstract][Full Text] [Related]
11. Cost-Efficient Detection of
Romanko AA; Mulkidjan RS; Tiurin VI; Saitova ES; Preobrazhenskaya EV; Krivosheyeva EA; Mitiushkina NV; Shestakova AD; Belogubova EV; Ivantsov AO; Iyevleva AG; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762506
[TBL] [Abstract][Full Text] [Related]
12. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
[TBL] [Abstract][Full Text] [Related]
13. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
[TBL] [Abstract][Full Text] [Related]
14.
Raphael A; Dudnik E; Hershkovitz D; Jain S; Olsen S; Soussan-Gutman L; Ben-Shitrit T; Dvir A; Nechushtan H; Peled N; Onn A; Agbarya A; On Behalf Of The Israel Lung Cancer Group
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566609
[TBL] [Abstract][Full Text] [Related]
15. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
Xia H; Xue X; Ding H; Ou Q; Wu X; Nagasaka M; Shao YW; Hu X; Ou SI
Clin Lung Cancer; 2020 May; 21(3):247-254. PubMed ID: 31761448
[TBL] [Abstract][Full Text] [Related]
16. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
[TBL] [Abstract][Full Text] [Related]
17. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract][Full Text] [Related]
18. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Kohno T; Nakaoku T; Tsuta K; Tsuchihara K; Matsumoto S; Yoh K; Goto K
Transl Lung Cancer Res; 2015 Apr; 4(2):156-64. PubMed ID: 25870798
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
20. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]